跳到正文
MMadical AI Use
廠商報告廠商

Quantitative assist for immunohistochemistry scoring

此語言的正文尚未翻譯,暫以英文顯示。

Vendors including PathAI and Ibex offer algorithms that estimate staining extent, such as a Ki-67 or PD-L1 percentage, on a digitized slide. A pathologist checks the region and the number before it enters the report. This card does not restate concordance percentages, which are assay-specific and easy to over-read. The signed score remains a pathology result, not a model result.

臨床場景

Immunohistochemistry sign-out in a digital pathology lab, where the stain already has a clinical scoring scheme the tumor board expects.

工具與廠商

  • PathAI
  • Ibex

來源中報告了什麼

No concordance figure is copied here. Treat vendor white papers as vendor-reported until an independent study matches the assay you actually run.

來源

PathAI · 2025年2月1日 · 年份 2025

收入索引 2026年7月2日

打開來源

標籤

  • 病理
  • 人在環中
  • 計算機視覺

供教育和市場掃描的目錄條目。不是醫療建議,也不是背書。

病理

監管授權

Adjunct detection on prostate biopsy whole-slide images

Paige Prostate marks a location on a digitized prostate biopsy slide that the model ranks as the most suspicious for cancer, after the pathologist’s own first look. FDA authorized it in 2021 as an adjunct. The output is not the diagnosis. The pathologist still signs out, using the full clinical context and any extra stains they choose to order.

Paige Prostate · Paige FullFocus

新聞 · 2021閱讀案例

影像與放射

監管授權

Autonomous diabetic retinopathy screening in primary care

IDx-DR, now marketed as LumineticsCore by Digital Diagnostics, was authorized to screen adults with diabetes for more-than-mild diabetic retinopathy without an eye specialist reading the photo first. A primary care team captures images on a specified retinal camera and the software returns a refer-or-rescreen result. It is not a complete eye examination. Pregnancy and several existing retinal conditions sit outside the labeled use.

LumineticsCore (IDx-DR) · Digital Diagnostics · Topcon NW400

新聞 · 2018閱讀案例

影像與放射

已發表

AI-supported reading in the MASAI mammography trial

The MASAI trial in Sweden randomly assigned screening mammograms to AI-supported reading or standard double reading without AI. Transpara scored each exam and routed lower scores to a single reader and the highest score to double reading, with detection marks available on higher-risk exams. This card quotes the prespecified interim safety analysis, not a claim that every screening program should switch.

Transpara 1.7.0 · ScreenPoint Medical

論文 · 2023閱讀案例
贊助

向閱讀本目錄的臨床與健康科技讀者展示。

查看贊助